GAS5 and early-onset autosomal dominant Alzheimer disease: Consistently, GAS5 shows detrimental effects in neurological conditions like cerebral ischemic stroke [82,88,99,104], Parkinson’s disease [108,115], and Alzheimer’s disease [98], where its inhibition could offer an improvement in patient outcomes; however, GAS5 also demonstrates protective effects in conditions such as NAFLD [100], rheumatoid arthritis [118], and diabetic nephropathy [113,119], where the suppression of GAS5 could have potentially detrimental effects.